Skip to content
10-Q

Quarterly Report

AVENUE THERAPEUTICS, INC. ATXI

0001437749-26-015759

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 3.29M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$438K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.19M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.42M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $2.86M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.2M
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.83M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.27M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.1M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.27M
Total Liabilities Q1 2026 · Dec 31, 2025 $1.1M
Total Assets Q1 2026 · Mar 31, 2026 $2.47M
Total Assets Q1 2026 · Dec 31, 2025 $2.93M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.21
Eps Basic Q1 2026 · Mar 31, 2025 −$0.62
Sga Expense Q1 2026 · Mar 31, 2026 $514K
Sga Expense Q1 2026 · Mar 31, 2025 $1.49M
Rd Expense Q1 2026 · Mar 31, 2026 $200K
Rd Expense Q1 2026 · Mar 31, 2025 $411K
Net Income Q1 2026 · Mar 31, 2026 −$695K
Net Income Q1 2026 · Mar 31, 2025 −$1.85M
Operating Income Q1 2026 · Mar 31, 2026 −$714K
Operating Income Q1 2026 · Mar 31, 2025 −$1.91M